Manufacturing: Page 2
-
Sponsored by MilliporeSigma
From bench to batch: AAV manufacturing for the next-generation of gene therapies
Leveraging a CDMO’s established platform for AAV manufacturing can significantly streamline gene therapy development.
July 21, 2025 -
Private equity firms back PCI Pharma in bet on drug production
The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its geographic reach.
By Ben Fidler • July 14, 2025 -
National Resilience, a well-funded manufacturing startup, to scale back operations
The startup, which has raised more than $2 billion in funding to aid young biotechs with drug production, said its “capacity expansion has outpaced industry demand.”
By Gwendolyn Wu • June 10, 2025 -
Sponsored by Resilience
Navigating the evolving landscape of fill/finish: Challenges and what’s ahead
The demand for fill/finish services has never been greater, how are CDMOs responding?
May 27, 2025 -
Obesity drugs
Novo pressures GLP-1 compounders as FDA ban takes hold
The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off versions that have dented its sales forecasts.
By Kristin Jensen • May 22, 2025 -
Sponsored by PHIL
Bridging the data gaps that impact retail and specialty-lite success
Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.
May 19, 2025 -
Sponsored by West Pharmaceutical Services
How regulatory convergence is raising the bar for sterile drug safety—and how West leads the way
Global regulators continue to raise the bar on sterile drug manufacturing—and West is responding.
May 19, 2025 -
Pharma reshoring
Sanofi to pour more than $20B into US drug research and manufacturing
The French drugmaker joined several peers in promising new investments in U.S. drug production, but cautioned plans could change amid shifting Trump administration policies.
By Kristin Jensen • May 15, 2025 -
Pharma reshoring
Gilead, bracing for tariffs, joins peers in US drug production push
The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and operational investments in U.S. drug manufacturing.
By Kristin Jensen • May 8, 2025 -
Trump orders FDA to help speed building of new drug factories
Yet regulatory relief for U.S. expansion could be accompanied by new tariffs and drug pricing rules.
By Jonathan Gardner • May 6, 2025 -
Pharma reshoring
Pharma downplays tariff threat, even as risks remain unclear
Drugmaker executives have projected confidence they can mitigate the impact of any levies Trump imposes on the industry. Yet they're adjusting inventory and production nonetheless.
By Ned Pagliarulo , Jonathan Gardner • May 1, 2025 -
Merck takes $200M tariff hit, trimming its gross profits
The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.
By Jonathan Gardner • April 24, 2025 -
Pharma reshoring
Roche, answering tariff threat, pledges $50B to US drug production
The big pharma joined several of its peers in committing to invest billions of dollars in new and expanded manufacturing facilities in the U.S., among them a gene therapy plant in Pennsylvania.
By Jonathan Gardner • April 22, 2025 -
Trump administration
US launches probe that could set stage for pharma tariffs
The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.
By Ned Pagliarulo • Updated April 14, 2025 -
Pharma reshoring
Amid tariff turmoil, Novartis commits to spending $23B on US manufacturing
Novartis expects the new capacity will allow it to produce all of its key medicines “end to end” in the U.S., as the Trump administration buffets global trade with tariffs.
By Jonathan Gardner • April 10, 2025 -
Trump administration
Trump pauses most reciprocal tariffs, hikes China’s further
Drug company shares, which had sunk on comments by Trump that pharma duties would be coming soon, rallied along with the broader market.
By Phil Neuffer • April 9, 2025 -
Trump administration
Medtech industry pressures White House to exempt devices from tariffs
AdvaMed and other healthcare groups have pleaded for the Trump administration to exempt medical devices and critical supplies.
By Ricky Zipp • April 8, 2025 -
Tariffs send healthcare industry into ‘unchartered waters’
Provider groups and health systems warn tariffs will test healthcare’s fragile supply chain, threatening to create disruptions to patient care.
By Susanna Vogel • April 4, 2025 -
Trump installs sweeping new tariffs, but pharma dodges blow
The president will impose a baseline 10% tariff on all countries, as well as higher levies on certain nations. Pharmaceutical goods appear to be exempt, at least for now.
By Phil Neuffer • Updated April 3, 2025 -
Pharma reshoring
J&J boosts US manufacturing as big pharma reshores
Following big announcements from Lilly and Merck, J&J is pledging $55 billion over the next four years to open new plants.
By Jonathan Gardner • March 21, 2025 -
Sponsored by QIAGEN Digital Insights
NGS is changing GxP compliance. Will you adapt?
Discover NGS for GxP compliance with full audit trails, operational control and robust data security.
By QIAGEN Digital insights • March 17, 2025 -
Viking inks CordenPharma deal to boost obesity drug supply
The biotech will commit $150 million to an alliance that hands it significant production capacity for a closely watched weight loss treatment.
By Jonathan Gardner • March 11, 2025 -
Merck opens $1B vaccine plant in North Carolina
Unveiling of the new factory comes as Merck and other pharma companies face pressure to reshore manufacturing back to the U.S.
By Delilah Alvarado • March 11, 2025 -
Sponsored by Syngene
SynWeave™: Revolutionizing biopharma manufacturing by improving titer, timelines and manufacturability
Enhancing manufacturability is crucial for reducing the risks associated with scaling production.
March 10, 2025 -
Pharma reshoring
Lilly CEO wields manufacturing plans to push pharma-friendly policies
While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and changes to Medicare's drug negotiation program.
By Ned Pagliarulo • Feb. 26, 2025